Verywell Health on MSN
Symptoms of metastatic castration-resistant prostate cancer
Medically reviewed by Jamin Brahmbhatt, MD Metastatic castration-resistant prostate cancer (mCRPC) is a type of advanced ...
Nubeqa (darolutamide) received FDA approval for metastatic castration-sensitive prostate cancer, showing significant improvement in radiographic progression-free survival. The ARANOTE trial involved ...
Findings showed darolutamide reduced the risk of radiographic progression or death by 46% compared with placebo. The Food and Drug Administration (FDA) has approved Nubeqa ® (darolutamide), an ...
Akeega reduced radiographic progression or death risk by 37% in mCSPC patients with HRR gene alterations. Significant reduction in symptomatic progression risk by 50% and a trend towards improved ...
When compared to tumors from European American men with mCRPC, African American men with mCRPC demonstrated a higher expression of MYC pathway genes and lower expression of IFN-γ, IL-6/JAK/STAT3 and ...
Integration of genomic classification and clinical characteristics as a predictor of survival in de novo metastatic prostate cancer. This is an ASCO Meeting Abstract from the 2026 ASCO Genitourinary ...
In patients with BRCA2-mutated mCSPC, treatment with Akeega significantly reduced the risk of radiographic progression or death by 54%. The Food and Drug Administration (FDA) has approved Akeega ® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results